atorvastatin + dapagliflozin

Atorvastatin + dapagliflozin is a combination therapy being investigated for its effects on lipid profiles and pharmacokinetic interactions in patients with ischemic heart disease and heart failure. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that lowers LDL cholesterol by inhibiting the rate-limiting enzyme in hepatic cholesterol synthesis. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose levels by preventing glucose reabsorption in the renal proximal tubules, leading to glycosuria. This specific combination is the subject of a prospective clinical study (NCT06520891) led by Fayoum University to evaluate pharmacokinetic interactions and additive effects on lipid metabolism (cholesterol, LDL, HDL, and triglycerides) in patients with cardiovascular disease. The regimen is studied as a co-administration of two separate agents rather than a fixed-dose combination product.

Other names

statin + SGLT2iatorvastatin and dapagliflozinatorvastatin and dapagliflozin combination